[New developments in the treatment of oligozoospermia].
New developments in the treatment of oligozoospermia are discussed and critically considered. In particular, the necessity of performing double blind studies to test the efficacy of a drug is stressed. Generally, there is a great need for clinically orientated basic research in andrology since new approaches to scientifically orientated therapy are only possible if our current knowledge on physiology and pathophysiology of male reproductive functions is improved. In addition, a rational therapy can only be performed if sufficient selection criteria are available. The variety of new therapeutic means indicate that in the near future different approaches will be investigated to improve the success of andrological treatment, thus rendering therapy more effective for patients and doctors.
D004311:Double-Blind Method; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009845:Oligospermia / Q000097:blood / Q000188:drug therapy*; D010889:Piracetam / Q000627:therapeutic use; D010906:Pituitary Hormone-Releasing Hormones / Q000097:blood; D013076:Sperm Count / Q000187:drug effects; D013081:Sperm Motility / Q000187:drug effects; D013738:Testolactone / Q000627:therapeutic use; D013739:Testosterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D014646:Varicocele / Q000150:complications
D010906:Pituitary Hormone-Releasing Hormones; D013739:Testosterone; D013738:Testolactone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C010792:testosterone undecanoate; D010889:Piracetam
Neue Entwicklungen in der Behandlung der Oligozoospermie.